Market closed

Capricor/$CAPR

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Capricor

Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

Ticker

$CAPR
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
San Diego, United States

Employees

102
Website
www.capricor.com

Capricor Metrics

BasicAdvanced
$578M
-
-$1.07
4.02
-

$578M

4.02

$21.01

$3.52

1.4M

4.192

4.173

1.223

2.415

-34.73%

-102.63%

17.387

35.37

35.37

-10.538

65.33%

-6.71%

324.93%

9.64%

What the Analysts think about Capricor

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Capricor stock.

Capricor Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Capricor Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Capricor News

AllArticlesVideos
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

GlobeNewsWire·2 weeks ago
Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached

Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached

Seeking Alpha·1 month ago
Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission

Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission

Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CAPR

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Capricor stock?

Capricor (CAPR) has a market cap of $578M as of January 15, 2025.

What is the P/E ratio for Capricor stock?

The price to earnings (P/E) ratio for Capricor (CAPR) stock is 0 as of January 15, 2025.

Does Capricor stock pay dividends?

No, Capricor (CAPR) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Capricor dividend payment date?

Capricor (CAPR) stock does not pay dividends to its shareholders.

What is the beta indicator for Capricor?

Capricor (CAPR) has a beta rating of 4.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.